Clinical Aspects of Aconitum Preparations*

Authors
Chi-Jung Tai1,3 #, Mohamed El-Shazly1,2,4, Tung-Ying Wu1, Kun-Tai Lee1,5,6, Dezső Csupor7, Judit Hohmann7, Fang-Rong Chang1,8,9,10,11,12, Yang-Chang Wu1,4,11,12

Affiliations
The affiliations are listed at the end of the article

Key words
- Aconitum
- Ranunculaceae
- monkshood
- traditional Chinese medicine
- Ayurvedic medicine

Abstract

Aconite species have played an important role in human history. Aconitum species have been used worldwide as poisons as well as remedies. Their potential in targeting several ailments such as pain, rheumatism, and lethargy has been recognized by Western, Chinese, and Indian health care practitioners. Aconite use in herbal preparations has declined, especially in Europe and the United States, in the first half of the twentieth century due to several reported toxicity cases. The situation has changed with the application of new technologies for the accurate analysis of its toxic components and the development of efficient detoxification protocols. Some Asian countries started small clinical trials to evaluate the potency and safety of different marketed aconite preparations. The current review summarizes therapeutic uses of aconite preparations in China, Taiwan, India, and Japan. It also highlights clinical trial results with special emphasis on their limitations. Modern drugs and pharmacopeial preparations derived from aconite are also discussed.

Introduction

Aconitum, also known as monkshood, wolf’s bane, or devil’s helmet, has been widely used in folk medicine in China, India, and certain parts of Europe [1–4]. The genus Aconitum (Ranunculaceae) comprises 300 species distributed all over the world [5]. The most common species are Aconitum carmichaeli Deb. and Aconitum kusnezoffii Rchb. in China, Aconitum japonicum Thunb. in Japan, Aconitum napellus L. in Europe, Aconitum ferox Wall. ex Ser. in India, and Aconitum noveboracense A. Gray ex Coville in the United States [5]. Several classes of secondary metabolites, especially alkaloids, have been isolated from different Aconitum sp. [6]. The type of the isolated major alkaloids may vary depending on the species such as aconitine, hypaconitine, and mesaconitine from A. carmichaelii, aconitine from A. napellus, hypaconitine from A. septentrionale Koelle, mesaconitine from A. kusnezoffii, bikhaconitine from A. ferox, talatisamine from A. kongboense Lauener, atisine from A. anthora L., and A. heterophyllum Wall. ex Royle, and lycaconitine from A. vulparia Rchb. [6]. Several isoquinoline alkaloids and phe-nethylamine derivatives have also been isolated, such as higenamine from A. japonicum, magnoflorine from A. vulparia and A. napellus, corynine from A. carmichaelii, and N-methyl adrenaline from A. nasutum Fisch. ex Rchb. [6]. Lipo-alkaloids including lipoaconitines, lipomesaconitines, lipodeoxyaconitines, and lipohypaconitines were also isolated [7,8].

The efficacy of Aconitum sp. in resolving critical clinical conditions has been proven by doctors practicing traditional Chinese medicine (TCM) and Ayurvedic medicine for centuries. However, the long history of Aconitum sp. misuse in homicide cases has shaken the faith in the potential safe application of this herb in therapy [9,10]. The recent developments in analytical techniques which can identify and determine the concentrations of toxic compounds in herbal products with impressive accuracy and reliability have rekindled the interest in Aconitum preparations [1,5,6,11,12]. A plethora of studies have focused on developing accurate, feasible, and fast analytical techniques to determine the alkaloidal content in each aconi-
ite preparation using trivial analytical equipment available in almost all analytical laboratories [13–18]. Also, the biological effects of different *Aconitum* sp. *in vitro* and *in vivo* have been studied in depth, revealing the molecular targets of each major component [19–21]. Recently, studies reporting the clinical applications of different *Aconitum* preparations have revealed promising results in terms of safety and efficacy [22, 23]. However, an overview summarizing clinical studies on *Aconitum* sp., which can help in further developments, is still lacking. This review aims to provide a comprehensive summary of the clinical applications of *Aconitum* preparations. To fully understand the potential of this herb in therapy, a short introduction on the clinical use of *Aconitum* sp. throughout history based on reliable historical records is presented.

### Traditional Chinese Medicine

*Aconitum* was first introduced in *Shennong Ben Cao Jing*, which is the earliest Chinese herbs book and might be written around the era of Qin to Western Han Dynasties (221–200 BC) [24, 25]. *Aconitum* preparations, including Fuzi (aconiti radix lateralis praepara-tarum), Wutou (chuan wu, aconiti radix praepara-tarum), and Caowu (*A. kusnezoffii*), have been recommended for cold limbs, painful knees, walking difficulties, chronic wounds, poor circulation, spasms, and different tumors [3].

The applications of *Aconitum* were advocated in *Shang Han Lun*, which was written by Zhang Zhongjing, one of the most respected TCM physicians in history. He lived in the Eastern Han Dynasty around 150–209 AD [26]. He introduced some formulas [**Table 1**] targeting critical health problems using Fuzi as the main therapeutic agent. In addition to the indications summarized in *Shang Han Lun*, Fuzi was mainly used to treat patients with general weakness, fatigue, drowsiness, cold extremities, abdominal pain, body pain, and weak pulse. It was believed that Fu-zi was highly effective in improving body circulation [5, 27–29].

*Aconitum* toxicity remained a major concern to TCM practitioners, and many prominent physicians in the Ming to Qing Dynasties were afraid to use Fuzi in herbal formulas [5]. This cautious trend continued until the renaissance TCM theory in the Han to Tang Dynasties. The physicians living in this period found out that following therapeutic theories introduced by Zhang Zhong-jing resulted in impressive results. Spreading this knowledge to the rest of the world started in the nineteenth century with the surge of migration waves from China to Western countries [30]. Many TCM practitioners found that *Aconitum* played an important role in the history of Western civilization as a lethal herb and as a medication. Through combining knowledge accumulated over centuries from Eastern and Western civilizations, TCM practitioners started to advocate the use of *Aconitum* against several ailments. Hai-Ha Ni (1954–2012) in the USA, Buto-Chang (1942–2012) in Taiwan, Chin-An Zheng (1824–1911) in China, and other prominent TCM physicians introduced different therapeutic regimens containing Fuzi. *Aconitum* was prescribed for its cardiotonic, antiarrhythmic, analgesic, anti-epileptiform, anticancer and antimicrobial activities [3]. In order to maximize the clinical effects, some followers of Chin-An Zheng recommended the use of raw or processed Fuzi in a dose as high as 60–120 g, which was 4–8 times the dosage recommended by previous practitioners. However, the pros and cons of high doses of Fuzi were not investigated.

Practitioners have differentiated in their recommendations between raw and processed Fuzi. In general, raw Fuzi was administrated in more critical conditions, while the processed preparation was used to increase circulation and energy [5]. Recent scientific studies showed that the toxicity of raw Fuizi is reduced by processing due to the hydrolysis of the ester group of the diester-diterpenoid alkaloids (aconitine, mesaconitine, and hypaconi-tine) (†[Fig. 1]) [4]. Initially, the acetyl group is hydrolyzed and in the second step, the benzoyl group is hydrolyzed (†[Fig. 2]) [17]. This process results in an increase in the concentrations of monoster-diterpenoid alkaloids (benzoylconnine, benzoylmesaconine, and benzoyllycopaconine) in the processed Fuizi [18]. Also, the concentration of lipo-alkaloids, which are esters of alkaloids with fatty acids in the C-8 position, significantly increased after processing (†[Fig. 3]) [8]. However, there is no detailed clinical study showing the differences in pharmacological activity and toxicity between raw and processed Fuizi. Therefore, it is important to conduct such studies on a reasonable scale to demonstrate the potential and limitations of raw and processed Fuizi. One of the important steps to tackle this problem is the ongoing randomized control trial to evaluate the efficacy of Sini Tang, which uses raw Fuzi, in patients with septic shock [31]. It is hoped that such trials will provide health care authorities with essential in-

---

**Table 1** Famous formulas with Fuzi.

<table>
<thead>
<tr>
<th>Formula</th>
<th>Ingredients</th>
<th>Fuzi dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sini Tang</td>
<td><em>Aconitum carmichaeli</em> (<em>Raw</em> Fuzi), <em>Zingiber officinale</em> (Ganjiang), and <em>Glycyrrhiza uralensis</em> (roasted Gancao, licorice)</td>
<td>1 piece (15–30 g)</td>
</tr>
<tr>
<td>Bai Tong Tang</td>
<td><em>Allium fistulosum</em> L. (white stem of shallot), <em>Zingiber officinale</em> (Ganjiang), and <em>Aconitum carmichaeli</em> (<em>Raw</em> Fuzi)</td>
<td>1 piece (15–20 g)</td>
</tr>
<tr>
<td>Fuzi Lixiang Tang</td>
<td><em>Aconitum carmichaeli</em> (<em>Processed</em> Fuzi), <em>Panax ginseng</em> (ginseng), <em>Zingiber officinale</em> (Ganjiang), <em>Atractylodes macrocephala</em> Koidz. (Bai Zhu), <em>Glycyrrhiza uralensis</em> (roasted Gancao, licorice)</td>
<td>1 piece (15–20 g)</td>
</tr>
<tr>
<td>Ma Huang Fu Zhi Hsin Tang</td>
<td><em>Ephedra sinica</em> (Ma Huang), <em>Aconitum carmichaeli</em> (<em>Processed</em> Fuzi), and <em>Asarum sieboldii</em> (His Hsin)</td>
<td>1 piece (15–20 g)</td>
</tr>
<tr>
<td>Jen Wu Tang</td>
<td><em>Porzia cocos</em> F. A. Wolf. (Fu Ling), <em>Poria lactiflora</em> Pallas. (Shaoyao, Chinese peony), <em>Zingiber officinale</em> (fresh ginger), <em>Atractylodes macrocephala</em> Koidz. (Bai Zhu), and <em>Aconitum carmichaeli</em> (<em>Processed</em> Fuzi)</td>
<td>1 piece (15–20 g)</td>
</tr>
<tr>
<td>Fuzi Tang</td>
<td><em>Aconitum carmichaeli</em> (<em>Processed</em> Fuzi), <em>Porzia cocos</em> F. A. Wolf. (Fu Ling), <em>Panax ginseng</em> (ginseng), <em>Atractylodes macrocephala</em> Koidz. (Bai Zhu), and <em>Poria lactiflora</em> Pallas. (Shaoyao, Chinese peony)</td>
<td>2 pieces (30–40 g)</td>
</tr>
<tr>
<td>Ma Huang Fu Zhi Cancao Tang</td>
<td><em>Ephedra sinica</em> (Ma Huang), <em>Aconitum carmichaeli</em> (<em>Processed</em> Fuzi), <em>Glycyrrhiza uralensis</em> (roasted Gancao, licorice)</td>
<td>1 piece (15–20 g)</td>
</tr>
</tbody>
</table>
formation to establish the necessary measures and regulations of *Aconitum* use.

**Current Herbal Formulas in China**

In China, many scientists, physicians, and pharmaceutical companies work together to create new *Aconitum*-based formulas. Many different hospitals create their own formulas and they also try to formulate *Fuzi* into pills, capsules, and injections instead of traditional decoctions [28, 29]. The clinical results of different *Aconitum* formulas reported in English are summarized below.

**Qili-qiangxin capsules**

The qili-qiangxin capsule was developed and approved in 2004 by the Chinese Food and Drug Administration for the treatment of heart failure [32]. Its development was based on the theory of TCM. The formula contains 11 distinct herbs, in which astragalus radix and aconiti lateralis radix preparata (*Fuzi*) are the principal pharmacologically active components.

One thousand capsules were prepared from ginseng radix et rhizoma (225 g), astragali radix (450 g), aconiti lateralis radix preparata (112.5 g), semen descurainiae lepidii (150 g), *Salvia miltiorrhiza* Bunge (Lamiaceae) radix et rhizome (225 g), alismatis rhizoma (225 g), ramulus cinnamomi (90 g), polygonati odorati rhizoma (75 g), periplocae cortex (150 g), carthami flos (90 g), and citri reticulatae pericarpium (75 g) [33]. Each capsule was 0.3 g, and patients were advised to take four capsules each time three times a day.

The clinical efficacy of qili-qiangxin capsules in treating heart failure was proved after the publication of a double-blind, multi-center, placebo-controlled, prospective, randomized clinical trial in 435 patients with chronic heart failure in 2013 [34]. Patients included in the trial were diagnosed with heart failure and were found to belong to class II–IV according to the New York Heart Association (NYHA) functional classification. They suffered from a left ventricular ejection fraction (LVEF) ≤ 40% and a serum NT-proBNP (N-terminal pro-B-type natriuretic peptide) level ≥ 450 pg/mL. The possible causes of heart failure were cardiomyopathy (56.82%), ischemic heart disease (32.59%), or hypertension (19.75%). In addition, 15.48% of the patients had a medical history of atrial fibrillation and 16.7% had diabetes mellitus.

The results showed that the qili-qiangxin capsule group demonstrated improved symptoms compared to the placebo group after 12 weeks of follow-up. Patients in the qili-qiangxin capsule group (47.95%) showed a reduction in plasma NT-proBNP compared with 31.98% of the patients in the placebo group. Treatment with qili-qiangxin capsules also resulted in superior performance in comparison to the placebo group with respect to NYHA functional classification, LVEF, 6-min walking distance, and quality of life. The detailed mechanism of the qili-qiangxin capsule in treating heart failure is not well established yet. An animal study showed that the qili-qiangxin capsule could downregulate the ratio of tumor necrosis factor-α/interleukin-10 and improve cardiac function in mice with myocardial infarction [35]. It also inhibited myocardial inflammation and the death of cardiomyocytes. On the other hand, it promoted cardiomyocyte proliferation, leading to improved cardiac remodeling and cardiac function [36]. Another study showed that qili-qiangxin improved both systolic and diastolic cardiac functions, and it downregulated the cardiac chymase signaling pathway and chymase-mediated angiotensin II production in hypertensive rats [37]. The other cardioprotective effects of qili-qiangxin were related to the regulation of the glycolipid substrate metabolism by activating AMPK (AMP-activated protein kinase)/PGC-1α (peroxisome proliferators-acti-
vated receptor-γ coactivator-1α) axis. Also, it was suggested that qili-qiangxin reduced the accumulation of free fatty acids and lactic acid protecting cardiac myocytes and mitochondrial function [38].

Regarding the electrophysiological aspects of qili-qiangxin, it was found that the capsule blocks ICa-L (L-type Ca2+ channel) and reduces Ca2+ overload. These effects can improve the heart rate similar to the effect of antiarrhythmic agents and improve the overall condition of the heart [39]. Qili-qiangxin was also found to decrease the sodium current (INa), transient outward K+ current (Ito), and activate the delayed rectifier outward K+ current (IK) on cardiac ventricular myocytes [40]. These results suggested the potential application of qili-qiangxin capsules as a treatment for heart failure and arrhythmia.

Shenfu injection

Shenfu injection (SFI) is one of the modern formulations of Chinese medicine, which is prepared from red ginseng [steamed roots of Panax ginseng C.A.Mey. (Araliaceae)] and aconite (processed lateral roots of A. carmichaelii) by using countercurrent extraction and macroporous resin adsorption chromatography [41]. A total of 44 components were identified by the high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (HPLC-QTOF MS) method [41]. An LC-MS method with selected ion monitoring was used to quantify 24 major alkaloids and ginsenosides. The total content of ginsenosides was found to be 676–742 µg/mL, while the alkaloids were present in trace amounts (3–7 µg/mL). In the SFI sample, ginsenosides Rb1 Rg1, and Re were the predominant components, followed by Rc, Rf, and Rb2.

Its clinical application was evaluated against a myriad of ailments including heart failure, septic shock, intradialytic hypotension, post-resuscitation care, cancer, and neuroprotection. A systemic review and meta-analysis study were conducted to evaluate the efficacy of SFI for the treatment of heart failure [42]. The mortality rate in patients with myocardial infarction-induced heart failure was significantly decreased in the shenfu injection (SFI) group. However, the mortality rates in patients with heart failure that was not caused by myocardial infarction was not affected by SFI. On the other hand, the cardiac function in the SFI group was improved according to NYHA classification, not only in myocardial infarction-induced heart failure but also in non-myocardial infarction-induced heart failure. The results of echocardiography also showed that SFI combined with routine treatment such as beta-blockers, ACEI, antihypertensive agents, and diuretics improved left ventricular ejection fraction (LEVF), cardiac output, stroke volume, and the cardiac index (CI) in heart failure patients. SFI also improved the E/A ratio [the ratio of the early (E) to late (A) ventricular filling velocities]. In a healthy heart, the E velocity is greater than the A velocity. In certain pathologies and with aging, the left ventricular wall can become stiff, increasing the back pressure as it fills, which slows the E filling velocity, thus lowering the E/A ratio [43]. The reversal of the E/A ratio (A velocity becomes greater than E velocity) is often accepted as a clinical marker of diastolic dysfunction, suggesting that diastolic function was improved in the SFI group. In the evaluation of biological parameters, SFI significantly reduced NT-proBNP levels and increased the distance of 6-min walking. However, there was no significant difference in blood pressure between the SFI and routine treatment groups.

In the treatment of intradialytic hypotension (IDH), SFI also showed a beneficial effect in hemodialytic patients. Eight randomized, controlled clinical trials were performed with 348 participants during 7974 hemodialysis sessions to evaluate the effect of SFI [44]. The results showed that SFI significantly increased systolic blood pressure but not diastolic blood pressure. The SFI group also showed an improved clinical effective rate compared with the control group. SFI reduced the incidence of hypotension when used to prevent or to treat an episode of intradialytic hypotension (IDH). The albumin level was increased but the C-reactive protein (CRP) level was decreased in patients treated with SFI. No significant side effects were reported. For the management of septic shock, one Chinese systemic review, which included 499 patients in six randomized, controlled trials, concluded that SFI could increase systolic and diastolic blood pressure [45]. It also improved shock symptoms and reduced the heart rate.

Other studies tried to evaluate the effect of SFI in improving the quality of life as well as in treating cancer-related fatigue and anemia [46, 47]. However, the presented results were insignificant. In general, well-organized, controlled clinical trials should be conducted to evaluate the previously reported Shenfu animal studies. These reports indicated that Shenfu acted as a coronary dilator [48] as well as a neuroprotective agent after cardiac arrest [49], post-resuscitation care [50], acute pancreatitis [51], and hypoxic-ischemic brain injury [52]. In addition to qili-qiangxin capsules and SFI, many hospitals are trying to develop other kinds of Fuzi-related formulations with special emphasis on its cardiotonic effect. It is recommended that clinical trials should be conducted in different countries and not only restricted to China to fully exploit the benefits of Aconitum preparations.

Aconitum in Ayurvedic Medicine

Ayurvedic medicine is the Indian traditional medicinal system. Ayurvedic medicine includes the use of herbal, mineral, or metal products as well as surgical techniques and massages. The origin of Ayurvedic medicine is unclear. Some records in Atharvaveda might be written around 1500–1000 BC [53–56]. These records contain 114 hymns and incantations described as magical cures for different diseases, forming the origin of Ayurvedic medicine [53].

Different Aconitum sp. were used by practitioners of Ayurvedic medicine in the preparation of herbal formulas targeting several disorders. However, scientific literature lacks reports on clinical trials evaluating Ayurvedic herbal formulas containing Aconitum. Information on the clinical efficacy of Aconitum preparations comes from the traditional use of this herb over centuries [57, 58]. There are 11 Aconitum sp. used in Ayurvedic medicine. They are used as anti-inflammatoty, antiemic, antirheumatic, and anti diarrheal agents. The details are summarized in Table 2 [57].

Current Applications of Fuzi in Taiwan

In Taiwan, Fuzi is strictly regulated due to its toxicity. According to the Taiwan Herbal Pharmacopeia, the total concentration of diester-diterpenoid alkaloids (aconitine, mesaconine, and hypaconitine) should not be above 0.020% in crude Fuzi materials. On the other hand, the total concentration of monoester-diterpenoid alkaloids (benzoylaconine, benzoylmesaconine, and benzoylhypaconine), the less toxic alkaloids, should be over 0.010% [59]. The suggested dosage of crude Fuzi is 3–15 g.
Table 2  Common Aconitum species in Ayurvedic medicine.

<table>
<thead>
<tr>
<th>Species</th>
<th>Ayurvedic name</th>
<th>Action</th>
<th>Main alkaloid components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aconitum atrox</td>
<td>Vatsanaabba</td>
<td>Poison</td>
<td>1.2% Total alkaloids, psuedoaconitine (0.4%)</td>
</tr>
<tr>
<td>Aconitum chosunanthum</td>
<td>Visha, Shringka-Visha</td>
<td>Sedative, antirheumatic, analgesic, antiinflammatove, antiinflammative, antidiarrhea</td>
<td>Aconitine, mesaconitine, hypaconitine, 3-acetylaconitine, lappaconitine, benzoconitine</td>
</tr>
<tr>
<td>Aconitum deinnenziyum</td>
<td>Vatsanaabba</td>
<td>Rheumatism, rheumatic fever and acute headache</td>
<td>0.9% Total alkaloids, 0.4% psuedoaconitine</td>
</tr>
<tr>
<td>Aconitum falconeri</td>
<td>Vatsanaabba</td>
<td>Sedative; carminative; anti-inflammatory for the nervous system and digestive system</td>
<td>Bishatisine, bishaconitine, falconitine, and mitaconitine</td>
</tr>
<tr>
<td>Aconitum ferox</td>
<td>Vatsanaabba, Visha, Anriva, Vajraang, Garala</td>
<td>Narcotic, sedative, antileprotic, anti-inflammatove,</td>
<td>Diterpenoid alkaloids</td>
</tr>
<tr>
<td>Aconitum heterophyllum</td>
<td>Ativishaa, Arunaa, Visha, Shuklakandaa, Bhanguraa</td>
<td>Antiperiodic, fever, antispasmodic (abdominal pain and stomach), anti-inflammatory, astrin- gent (cough, diarrhea, dyspepsia)</td>
<td>0.79% Total alkaloids, atisin 0.4%</td>
</tr>
<tr>
<td>Aconitum lacinatum</td>
<td>Vatsanaabba</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aconitum luridum</td>
<td>Vatsanaabba</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aconitum palmatum</td>
<td>Prativishaa, Shyaamkandaa, Patis</td>
<td>Antiemetic, anti-diarrhea, antirheumatic, anti- periodic</td>
<td>Diterpenoid alkaloids, benzamide, vakooglobin, palmitamine, vakatsine, vakatisine, and vakatidine</td>
</tr>
<tr>
<td>Aconitum spicatum</td>
<td>Vatsanaabba</td>
<td>Antipyretic, analgesic</td>
<td>1.75% Alkaloids, mainly psuedoaconitine and bilhaconitine</td>
</tr>
<tr>
<td>Aconitum violaceum</td>
<td>Vatsanaabba</td>
<td>Nervine tonic</td>
<td>1% Indaconitine</td>
</tr>
</tbody>
</table>

There are not only crude preparations of Fuzi in Taiwan but also commercial products of Fuzi extraction concentrated powder/granules. However, some of the famous Fuzi formulations do not have commercial concentrated TCM powder. After our evaluation, the commercial powder/granule products only include pro- cessed Fuzi, Ma Huang Fuzi Hsi Hsin Tang, Fuzi Lzhong Tang, Sini Tang, Jen Wu Tang, and Guifu Dihuang Wan (Ba Wei Di Huang Wan).

We examined commercial concentrated Fuzi powder in two GMP TCM factories. The concentrations of alkaloids were quantified by HPLC-UV [60]. A commercial Fuzi powder (1 g) was extracted from 2.5 g crude drug in factory A. The concentrations of the total diester-diterpenoid alkaloids and monoester-diterpenoid alkaloids were ca. 12 and 16 ppm, respectively (10 ppm = 0.001%). On the other hand, a commercial Fuzi powder (1 g) was extracted from 3.35 g crude drug in factory B. The concentrations of the total diester-diterpenoid alkaloids and monoester-diterpenoid alkaloids were ca. 9 and 10 ppm, respectively. Compared with the requirement of crude Fuzi, the concentrations of toxic alkaloids were quite low. Therefore, the usage of commercial Fuzi powder/granule products is considered to be safer than crude Fuzi. Due to the difficulty of controlling the crude drug quality, it might be a good alternative to control the concentrated extract/granule powder products. It can help to set the standard criteria in many kinds of Fuzi formulas and it may be beneficial to investigate their efficacy in advanced clinical practice.

Aconite Preparations in Kampo Medicine

Kampo medicine is a Japanese medical system derived from TCM, which might have passed to Japan during the Tang Dynasty around 700–800 AD [61–63]. Kampo medicine focuses on herbs, acupuncture, and moxibustion. Many classical TCM books such as Huangdi Neijing, Shennong Ben Cao Jing, and Shanghan Lun set the standard of the treatment theory. Since then, Japanese doctors have improved the theory borrowed from TCM according to their clinical experiences and observations. Many famous Japa-
The famous aconite Kampo medicine preparations and their indications are listed in Table 3 [62,63,65,75]. It shows that Aconitum is applied in many different clinical situations. The efficacy of some formulations has been proven by small clinical studies. For example, Goshajinki-gan was shown to have a benefit in the treatment of lymphedema [75,76]. Some Kampo formulations are directly derived from TCM. For example, Shinbuto is similar to Jen Wu Tang, Shigakuto resembles Si Ni Tang, and Maobushisaishinto is derived from Ma Huang Fuzu Hsi Hsin Tang.

### Table 3 Formulas with aconite in Kampo medicine.

<table>
<thead>
<tr>
<th>Formula name</th>
<th>Ingredients</th>
<th>Indications/Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goshajinki-gan.</td>
<td>7.5 g of TSUMURA Goshajinkigan extract granules (TJ-107) contain 4.5 g of a dried extract of the following mixed crude drugs: Rehmannia root 5.0 g, achyranthes root 3.0 g, cornus fruit 3.0 g, dioscorea rhizome 3.0 g, plantago seed 3.0 g, alisma rhizome 3.0 g, poria sclerotium 3.0 g, moutan bark 3.0 g, cinnamom bark 1.0 g, powdered processed aconite tuber 1.0 g.</td>
<td>Patients with decreased urine volume or polyuria sometimes having dry mouth who are easily fatigued and easily feel cold in the extremities: Leg pain, low back pain, numbness, blurred vision in old patients, pruritus, dysuria, frequent urination, and edema. Usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals.</td>
</tr>
<tr>
<td>Hachimiji-gan.</td>
<td>7.5 g of TSUMURA Hachimijiogan extract granules (TJ-7) contain 4.0 g of a dried extract of the following mixed crude drugs: Rehmannia root 6.0 g, cornus fruit 3.0 g, dioscorea rhizome 3.0 g, alisma rhizome 3.0 g, poria sclerotium 3.0 g, moutan bark 2.5 g, cinnamom bark 1.0 g, powdered processed aconite root 0.5 g.</td>
<td>Patients with severe fatigue or malaise, decreased urinary output or increased urinary frequency, dry mouth, and alternate cold and hot feeling in the extremities: Nephritis, diabetes mellitus, impotence, sciatica, low back pain, beriberi, cystorrhea, prostatic hypertrophy, and hypertension. Usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals.</td>
</tr>
<tr>
<td>Keishikajutsubuto.</td>
<td>7.5 g of TSUMURA Keishikajutsubuto extract granules contain 3.75 g of a dried extract of the following mixed crude drugs: Cinnamon bark 4.0 g, peony root 4.0 g, atractylodes lancea rhizome 4.0 g, jujube 4.0 g, glycyrrhiza 2.0 g, ginger 1.0 g, aconite root 0.5 g.</td>
<td>Neuralgia, arthralgia. Usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals.</td>
</tr>
<tr>
<td>Shuchibushi N.</td>
<td>Aconitum carmichaelii root.</td>
<td></td>
</tr>
</tbody>
</table>

### Aconitum in Homeopathy

Homeopathy is a system of alternative medicine created by the German physician Samuel Hahnemann (1755–1843) [78]. Hahnemann advocated the principle that effective drugs produce symptoms in healthy individuals similar to those of the diseases that they treat, like cures like. He used herbal medicines to treat diseases. The first usage of A. napellus in homeopathy was recorded in Materia Medica Pura, which was written by Samuel Hahnemann in 1810. A. napellus was prescribed as an antipyretic and anti-inflammatory agent. It was also recommended to overcome fear, neuralgia, and urinary problems [79]. However, the effectiveness of A. napellus in homeopathy is still controversial. In a randomized, double-blind, controlled crossover study, A. napellus C30 (dilution of 10⁶⁰ times) yielded statistically significant results between the classified reactions compared with the placebo in healthy volunteers [80]. One prospective observational study showed similar efficacy of using different homeopathic remedies (A. napellus, Apis mellifica, Belladonna, Capsicum, Chamomilla, Kalium bichromicum, Lachesis, Lycopodium, Mercurius solubilis, Okoubaka, Pulsatilla, Sili-}

---


This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Clinical studies started in the 1980s, focusing on the effect of lappaconitine on the hemodynamics and myocardial contractility of patients with heart rhythm disorders [92]. The drug proved to be effective as class 1 C antiarrhythmic drugs. It was more effective than ethmozine and ethacizine in preventing ventricular and supraventricular extrasystoles. This effect was demonstrated in a clinical trial with patients suffering from arrhythmias of different etiology [93]. In paroxysmal ventricular tachycardia, lappaconitine hydrobromide had a similar efficacy to ethacizine and bonnecor [94], even in the case of long-term treatment [95]. In paroxysmal supraventricular arrhythmia, it exerted similar preventive antiarrhythmic efficacy to the class 1 antiarrhythmic drugs tachmalcor and propafenone [96]. According to a review on clinical trials, lappaconitine hydrobromide is especially effective in the prevention of paroxysmal atrial fibrillations [97]. A recently published study reported its efficacy in preventing ventricular premature beats [98]. Alapalin, similar to class IC antiarrhythmic drugs, causes a prolonged blockade of cardiomyocytes Na⁺ channels; however, contrary to other drugs such as lidocaine, it acts reversibly only on open channels. Moreover, recent studies revealed that lappaconitine hydrobromide decreased mRNA levels...
for the gene coding of certain K⁺- and Na+-channels and membrane transporter genes [99].

Furthermore, acetxetine (former name Guanfu base A), a diterpene alkaloid isolated from Aconitum koreanum R. Raymond, has been approved for the treatment of paroxysmal supraventricular tachycardia in 2005 in China [100]. In a study, patients with sustained supraventricular tachycardia using intravenous acetxetine hydrochloride showed comparable results to the group under propafenone [101]. In a further study, the intravenous administered alkaloid had similar efficacy to propafenone in controlling the premature ventricular contraction [102]. This compound blocks the fast Na⁺-channel, the delayed rectifier potassium current, and the L-type calcium current; however, it does not induce QT interval prolongation [100]. These two alkaloids are currently used in the market due to their favorable benefit-risk ratio compared to other, conventional antiarrhythmic drugs.

Toxicity of Aconite Preparations

The toxicity of Aconitum is notorious, as mentioned in all ancient records. Shakespeare highlighted the potency of this herb in his novel Romeo and Juliet, in which he stated that Romeo committed suicide using this poison [103]. Also, in Macbeth, the witches' brew calling for “tooth of wolf” refers to monkshood. Certain species are known also as wolfsbane because arrows dipped in the poison kill wolves. The emperor Trajan (98–117 AD) banned the growing of this plant in all Roman domestic gardens [104]. One of the most remarkable pieces, which described the role played by this plant in ancient Roman society, was summarized by the writer Ovid [104]. He referred to aconite as the “step-mother’s poison”. In the first Potions class in Hogwarts, Prof. Severus Snape informed Harry Potter about the toxicity of wolfsbane, which is the main ingredient of Wolfsbane Potion [105].

In recent years, many cases of Aconitum poisoning were published worldwide. Cases were concentrated in the Far East, with few cases in India or Europe. Until 2006, there were over 600 reported cases of Aconitum poisoning in China [106]. In Taiwan, 17 cases were reported from 1990 to 1999 [107]. In Hong Kong, the incidence of aconite poisoning was estimated to be 0.60 per 100000 populations from 1989 to 1993. But the annual incidence of herb-induced aconitine poisoning in the New Territories East in Hong Kong significantly decreased to 0.17 per 100000 populations after the publicity measures from 1996 to 1998 [108].

In general, Aconitum poisoning results from the direct oral intake of Aconitum decoctions or pills. Toxicity through dermal penetration is rare and only 14 cases of poisoning have been reported following the topical application of aconite preparations until 2011 [109]. In the two fatal cases, the epidermis and dermis at the sites of application were already damaged as a result of hot water scalding or herpes zoster infection. Both of the victims applied self-prepared aconite tincture, and one of them used raw “caowu (A. kusnezoffii)” 8 g and raw “chuanwu” 8 g in the application, which is even considered an overdose under normal circumstances. It was also suggested that the absence of an intact epidermis (stratum corneum) due to injury or diseases might significantly increase the systemic absorption of Aconitum alkaloids. To improve the safety of topical Aconitum preparations, alkaloid content is maintained as low as possible (0.119 mg per plaster) by manufacturers, but their use should be under medical supervision [110].

A study reported four “hidden” Aconitum poisoning cases, which did not include aconite in their prescriptions. Aconitum involvement was suspected due to the similarity of poisoning symptoms. Moreover, yunaconitine, which is not one of the common toxins (aconitine, hyaconitine, and mesaconitine), was also speculated to be involved in aconite toxicity [111]. Although it is uncommon, this may be just the tip of an iceberg with some cases going unrecognized.

The clinical presentation of Aconitum poisoning varies depending on the situation. From the experience of TCM doctors, the first symptom of Aconitum poisoning might be numbness of the tongue and lips. Other common symptoms are as follows: paresthesia and numbness over the face and limbs, nausea, dizziness, vomiting, abdominal pain, cold sweating, palpitations, bradycardia, tachycardia, hyperventilation, chest tightness, and hypotension. The mean latent period is 43.6 min [107], but it may differ depending on the dosage. Electrocardiography in these patients may show ventricular tachycardia, ventricular fibrillation, premature ventricular contractions, multifocal ventricular ectopics, sinus tachycardia, and bradycardia [107–109,112]. There is no specific dose-response relationship in these studies. Furthermore, it may elevate troponin-I and creatine kinase (CK), which mimics acute myocardial infarction [113].

The treatment of Aconitum poisoning depends on supportive care, some physicians tried MgSO₄, lidocaine, atropine, current shock, and a temporary pacemaker to correct patients' heart rhythm [107,112]. The toxicokinetic information is not well established in aconite poisoning. One study showed that the aconitine half-life is 3.7–17.8 h, its AUC is 2.4–5.1 ng × h/mL, and its mean residence time is 10.8–23.6 h. Mesaconitine half-life is 2.8–5.8 h, its AUC is 5.4–13.0 ng × h/mL, and its mean residence time is 9.7–11.9 h. Jesaconitine half-life is 5.8–15.4 h, its AUC is 6.9–33.5 ng × h/mL, and its mean residence time is 11.5–22.6 h. The range is wide because of the influence of liver and kidney function in herbal detoxification [112]. After appropriate treatment, most patients can recover without a specific sequela within eight days [107].

According to these studies, it is generally understood that the usage of Aconitum sp. should be under clinical supervision to prevent toxicity. More clinical trials should be conducted to reveal the optimum dosage, processing method, and formulations.

Detoxification Protocols

In ancient times, TCM practitioners tested several methods to reduce the toxicity of raw Fuzi. Some healers increased the decoction time, which led to a significant reduction in toxicity. Others mixed the herb with radix glycyrrhizae, P. ginseng, or Zingiber officinale Roscoe (Zingiberaceae) to decrease the toxicity of Fuzi and enhance its efficacy [114]. For example, Sini Tang is formed of radix glycyrrhizae (Gancao) and Z. officinale (Ganjiang) in combination with raw Fuzi. The effect of this preparation was attributed to the interaction between glycyrrhizin, liquiritin, and Fuzi alkaloids [115]. Furthermore, additional processing methods were developed over the years, including soaking in water, stirring, boiling, roasting, and steaming [116]. Some excipients were added during processing, including salts, green beans, licorice, and ginger, to reduce toxicity and improve efficacy. Yanfuzi, Heishunpian, Baifupian, Danfupian, and Paofupian are common processed products in Asian markets [106] (Table 5). All of the mentioned processing methods helped to...
reduce Fuzi toxicity by decomposing DDAs to the less toxic monoester-diterpenoid alkaloids (MDAs) [117]. After processing, the content of the highly toxic DDAs is generally reduced 40- to 70-fold compared to raw Fuzi.

Indian healers used different methods for the detoxification of aconite preparations known as Shodhana. It is based on treating the herb with cow dung, cow urine, or cow milk and subjecting the treated material to sunlight for a certain period of time using special containers [118]. Kampo practitioners added other nontoxic herbs to aconite roots such as cinnamon and atractylodes (Keishibukuryogan) as well as Ma-huang and asarum (Maobushisaiishinto) [119]. Asian decedents and Asian communities in other countries followed TCM practitioners detoxifying protocols with minor modifications [120].

The regulations of these toxic products differ among countries. It can only be imported or exported under strict regulations. The total amount of aconitine, hyaconitine, and mesaconitine should be less than 0.020% in aconite products in China and Taiwan [106]. In Japan and Europe, extra restrictions are applied and the concentration of toxic alkaloids (DDAs) is further reduced [121]. The concentrations of the nontoxic alkaloids should not exceed 3%, such as aconitic, malic, quinic, chlorogenic, and caffeic acid. In the USA and Canada, there are no specific regulations on Aconitum preparations, and reported toxic cases were mainly due to misdentification and misuse of the herb [122]. Different analytical techniques were developed to analyze and quantify the concentrations of aconite alkaloids, including HPLC, LC-MS, LC-MS/MS, and electrophoresis, with impressive accuracy and speed [3,17,18].

**Conclusion**

Aconite has been and will remain a mysterious herb. It is like Janus in Greek mythology with two faces, one supports healing and the other leads to death. Its long history of use did not eliminate suspicion and confusion about its true nature. TCM, Kampo, and Ayurvedic practitioners have studied this herb in depth and introduced a plethora of protocols to reduce its toxicity. Serious clinical trials have just started in China in the last decades aiming to reveal aconite’s true therapeutic potential. These trials suggested that qili-qiangxin capsules and SFI are efficient in treating heart diseases. Homeopathy and Ayurvedic therapeutic systems have used aconite for centuries, but without any reported clinical trials. Practitioners of Kampo medicine have performed small trials, which suggested potent aconite analgesic activity. Despite such attempts, the global official aconite usage is still in its infancy. It is recommended to conduct more clinical trials on different populations using available Aconitum sp. The results of these trials will assist health care authorities to regulate and control aconite preparations for the safety and benefits of patients.

**Acknowledgements**

This work was supported by grants from the Ministry of Science and Technology (MOST 103–2320-B-037-005-MY2; 102–2628-B-037-003-MY3; 103–29111-002–303; 104–29111-002–302; 103–2325-B-039–008; 103–2325-B-039–007–CC1), the National Health Research Institutes (NHRI-EX103–10241BI), and, in part, from a grant from the Chinese Medicine Research Center, China Medical University (the Ministry of Education, the Aim for the Top University Plan). This work was backed up by the Excellence for Cancer Research Center Grant, the Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan (MOHW104-TDU-B-212–124–003), a grant for Health and Welfare Surcharge of Tobacco Products, and Kaohsiung Medical University’s “Aim for the Top Universities Grant”, grant No. KMU-TP103. The processing information and material samples of Aconitum traditional Chinese medicine was also supported by Mr. Liang-Ying Chou at Sheng Chang Pharmaceutical Company and Dr. Shu Tian Chiang at Chuang Song Zong Pharmaceutical Company.

**Conflict of Interest**

The authors declare no conflict of interest.

**Affiliations**

1. Graduate Institute of Natural Products, Collage of Pharmacy, Kaoshiung Medical University, Kaoshiung, Taiwan
2. Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, Ain Shams University, Abassia, Cairo, Egypt
3. Department of Family Medicine, Kaoshiung Medical University Hospital, Kaoshiung Medical University, Kaoshiung, Taiwan
4. Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, Taiwan
5. Department of Internal Medicine, College of Medicine, Kaoshiung Medical University, Kaoshiung, Taiwan
6. Cardiovascular Center, Kaoshiung Medical University Hospital, Kaoshiung, Taiwan
7. Department of Pharmacognosy, University of Szeged, Szeged, Hungary
8. Research Center for Natural Product and New Drug Development, Kaoshiung Medical University, Kaoshiung, Taiwan
9. Cancer Center, Kaoshiung Medical University Hospital, Kaoshiung, Taiwan
10. Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaoshiung, Taiwan
11. School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan
12. Center of Molecular Medicine, China Medical University Hospital, Taichung, Taiwan

---

**Table 5** Common Fuzi detoxification protocols in China.

<table>
<thead>
<tr>
<th>Product name</th>
<th>Processing methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yanfuzi</td>
<td>Soaked with salts (MgCl₂ or NaCl) and dried in the sun. The surface of Fuzi is usually covered with salts.</td>
</tr>
<tr>
<td>Heishunpian</td>
<td>Soaked with salts and boiled in water, resulting in the formation of a transparent mass. This mass is sliced and brown sugar with oil is added giving the slices a brown color. Slices are then steamed, roasted, and dried.</td>
</tr>
<tr>
<td>Ballupian</td>
<td>Soaked with salts and boiled in water, leading to the formation of a transparent product. This product is sliced, steamed, and smoked with sulfur, rendering the slices white in color. Slices are then roasted and dried.</td>
</tr>
<tr>
<td>Danfupian</td>
<td>Yanfuzi is cleaned from salt by soaking in water. The product is sliced, boiled with licorice and black beans, and finally dried in the sun.</td>
</tr>
<tr>
<td>Paofupian</td>
<td>Yanfuzi salt is removed by soaking in water. The preparation is then sliced, soaked with ginger juice, roasted, and fried.</td>
</tr>
</tbody>
</table>